Jessica Difei Sun

Executive Director, Head Of In Vivo Pharmacology at Terremoto Biosciences

Jessica Difei Sun has over 25 years of work experience in the field of biosciences and pharmacology. Currently, they hold the position of Sr. Director, Head of In Vivo Pharmacology at Terremoto Biosciences since May 2022. Prior to this, they served as Sr. Director, In Vivo Pharmacology at ORIC Pharmaceuticals Inc. from February 2022 to May 2022, and as Director, In Vivo Pharmacology from December 2017 to February 2022.

Before joining ORIC Pharmaceuticals Inc., Jessica worked as the Director of In Vivo Biology at Reset Therapeutics from March 2016 to November 2017. At Reset Therapeutics, they led the In Vivo Biology team and served as the preclinical project leader for Cryptochrome modulators. Jessica Difei also managed contract research organizations (CROs) for various therapeutic areas such as cancer, rheumatoid arthritis, Type II diabetes, renal diseases, and nonalcoholic steatohepatitis (NASH). Additionally, they were involved in IND-enabling studies and IND submission.

Prior to their role at Reset Therapeutics, Jessica served as the Director of Pharmacology at Threshold Pharmaceuticals from 2007 to 2015. Jessica Difei started their career as a Scientist at Y's Therapeutics, Inc. from 2005 to 2007.

Before transitioning into the field of biosciences and pharmacology, Jessica worked as a Physician at China Medical University Affiliated 2nd Hospital from 1994 to 1997. In this role, they treated inpatients and provided acute care in the Internal Medicine Department and ER. Jessica Difei also conducted lectures for medical students and residents on internal medicine.

Overall, Jessica Difei Sun has a strong background in in vivo pharmacology, preclinical project leadership, and clinical medicine, making their a valuable asset in the biotech industry.

Jessica Difei Sun has a strong educational background in the field of medicine. Jessica Difei completed their MD in Clinical Medicine at China Medical University. Following this, they pursued a PhD in Medical Sciences (Histopathology) at Hamamatsu University School of Medicine. Jessica then went on to work as a Postdoctoral fellow at Stanford University School of Medicine. Additionally, they have also studied ADMET at UC San Diego.

Links

Peers

View in org chart

Timeline

  • Executive Director, Head Of In Vivo Pharmacology

    December 1, 2023 - present

  • Sr. Director, Head of In Vivo Pharmacology

    May, 2022